AEG-1 as a predictor of sensitivity to neoadjuvant chemotherapy in advanced epithelial ovarian cancer
Authors Wang Y, Jin X, Song H, Meng F
Received 17 December 2015
Accepted for publication 2 March 2016
Published 20 April 2016 Volume 2016:9 Pages 2385—2392
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Professor Min Li
Yao Wang,1,* Xin Jin,2,* Hongtao Song,3 Fanling Meng4
1Department of Gynecology and Obstetrics, 2Department of Intensive Care Unit, The General Hospital of Daqing Oil Field, Daqing, 3Department of Pathology, 4Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, People’s Republic of China
*These authors contributed equally to this work
Objectives: Astrocyte elevated gene-1 (AEG-1) plays a critical role in tumor progression and chemoresistance. The aim of the present study was to investigate the protein expression of AEG-1 in patients with epithelial ovarian cancer (EOC) who underwent debulking surgery after neoadjuvant chemotherapy (NAC).
Materials and methods: The protein expression of AEG-1 was analyzed using immunohistochemistry in 162 patients with EOC. The relationship between AEG-1 expression and chemotherapy resistance was assessed using univariate and multivariate logistic regression analyses with covariate adjustments.
Results: High AEG-1 expression was significantly associated with the International Federation of Gynecology and Obstetrics stage, age, serum cancer antigen-125 concentration, histological grade, the presence of residual tumor after the interval debulking surgery, and lymph node metastasis. Furthermore, AEG-1 expression was significantly higher in NAC-resistant disease than in NAC-sensitive disease (P<0.05). Multivariate analyses indicated that elevated AEG-1 expression predicted poor survival.
Conclusion: Our findings indicate that AEG-1 may be a potential new biomarker for predicting chemoresistance and poor prognoses in patients with EOC.
Keywords: AEG-1, epithelial ovarian cancer, neoadjuvant chemotherapy, interval debulking surgery
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]